Immune cells may guide therapy for oropharyngeal cancer
Source: www.medpagetoday.com Author: Charles Bankhead, Staff Writer, MedPage Today Higher pretreatment levels of cytotoxic T lymphocytes may help identify patients with head and neck cancer who have a favorable prognosis and require less aggressive treatment, according to a study reported here. A higher proportion of CD8 cells predicted improved survival in patients with oropharyngeal cancer associated with human papillomavirus-16 (HPV-16), investigators reported at the American Head and Neck Society. The finding supports the hypothesis that a patient's adaptive immunity may play a role in the favorable prognosis of HPV 16-related head and neck cancer. "We had hypothesized that a better immune status might be responsible for the better survival," Gregory T. Wolf, MD, of the University of Michigan in Ann Arbor, said in an interview. "The next step will be find out what the function of these cells might be and whether they are really contributing to the control of the cancer or to good response to therapy." The results also support the feasibility of using a biologic marker to identify patients with head and neck cancer that can be treated less aggressively, sparing patients from some of the treatment-related morbidity, Wolf added. Confirming the association between CD8 cells and survival is the latest step in a scientific journey that began about 15 years ago, when researchers and clinicians began to notice that a subgroup of patients with oropharyngeal cancer had a more favorable prognosis than would have been expected. Many of the patients tested positive for HPV, specifically HPV-16. [...]